U.S. markets closed
  • S&P 500

    3,666.72
    -2.29 (-0.06%)
     
  • Dow 30

    29,969.52
    +85.73 (+0.29%)
     
  • Nasdaq

    12,377.18
    +27.82 (+0.23%)
     
  • Russell 2000

    1,848.70
    +10.67 (+0.58%)
     
  • Crude Oil

    45.77
    +0.13 (+0.28%)
     
  • Gold

    1,844.30
    +3.20 (+0.17%)
     
  • Silver

    24.19
    +0.06 (+0.24%)
     
  • EUR/USD

    1.2149
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    0.9200
    -0.0280 (-2.95%)
     
  • GBP/USD

    1.3460
    +0.0007 (+0.05%)
     
  • USD/JPY

    103.7720
    -0.0880 (-0.08%)
     
  • BTC-USD

    19,431.77
    -19.73 (-0.10%)
     
  • CMC Crypto 200

    382.19
    +7.79 (+2.08%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,740.21
    -69.16 (-0.26%)
     

Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference

Osmotica Holdings US LLC
·1 min read

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual London Healthcare Conference as follows:

Date:

Wednesday, November 18, 2020

Time:

11:25 a.m. Eastern Time

Webcast:

https://wsw.com/webcast/jeff141/osmt/1873875

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations.

Osmotica has operations in the United States, Argentina, and Hungary.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com